Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 239 Publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MYDDfZRwfG:6aXOgRZN{[Xl? NHXOeFYyOCCwTR?= M{LVVVczKGh? NXzoZolRTE2VTx?= M4\yXHBwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=> NVjJdpZ{OjR7MEC4O|M>
HT-29 NUHGcpJOS3m2b4TvfIlkKEG|c3H5 NVXvSZN4OTBibl2= MWG3NkBp NX3a[lFQTE2VTx?= MVTQc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl? NFXTN2IzPDlyMEi3Ny=>
HT-29 NVrKfXM5S3m2b4TvfIlkKEG|c3H5 Ml73NVAhdk1? NXLzSoRHPzJiaB?= NGjXeHhFVVOR MmrZVI91\W62aXH0[ZMhPS2obIXvdo92emGlaXytbY5lfWOnZDDjfZRwfG:6aXPpeJk> NX:5O|g5OjR7MEC4O|M>
PC3 MlT0T4lv[XOnIFHzd4F6 MUOxNFAhdk1? NWHVR4d4OSCq M{OzeWROW09? NVPJOFN7WG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDxzMDDuUU4> MoP0NlE6Pzh4OEO=
PC3 NETrR|JMcW6jc3WgRZN{[Xl? NIf3N2cyODBibl2= NGHJN3EyKGh? MnL2SG1UVw>? MkW4SI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? NHnFOZgzOTl5OE[4Ny=>
PC3 MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT4dIgyNjVizszN NWrhSHdOOSCq NF76UnJFVVOR Mn7LTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyC5aYToJGlEPTBib3[gQFExKG6P M3XK[lIyQTd6Nkiz
HEK293 NYDk[HF{TnWwY4Tpc44hSXO|YYm= Mnv3NVAxKG6P NYi5[m9tQCCq MnzCSG1UVw>? M{jk[mlvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?= M4\xSFIyPTN7M{Cx
BT-20 MoTYT4lv[XOnIFHzd4F6 Mmr0NlAh|ryP NUjTUZVpTE2VTx?= Moq0SI9meyCwb4SgbY5pcWKrdDDtWG9TSzJiZHXw[Y5l\W62IIDBb3QhWzR5MzDwbI9{eGixconsZZRqd25? NXn5T3pkOjF|NUO1OVE>
U937 M{njOWFvfGmkYXP0[ZJq[WxiQYPzZZk> MmDnOVAh|ryP NXHvWGZzPDhiaB?= MnS4SG1UVw>? NXTDUJlVUW6mdXPld{BidnSrYnHjeIVzcWGuIHHjeIl3cXS7IHHnZYlve3Rid3ns[EB1gXCnIFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhWGirbHHk[YxxcGmjLUGgTnI{OiCrbjDVPVM4KGOnbHzz Ml;3NlEyPDJzME[=
U937 NWXub|RUSW62aXLhZ5RmemmjbDDBd5NigQ>? NYSxe4E6PTBizszN MYq0PEBp NEHLW4VFVVOR M17wSmRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhVUmSIIDyc5RmcW5vZHXmbYNq\W62IFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhUlJ|Mj2yJIlvKFV7M{egZ4VtdHN? MVqyNVE1OjFyNh?=
U937 MnLFRY51cWKjY4TldolidCCDc4PhfS=> MW[1NEDPxE1? MVe0PEBp M2XjOmROW09? MnLESI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM> MVKyNVE1OjFyNh?=
MCF-7 NUjKcVlOSXW2b4DoZYd6KEG|c3H5 NUHyWWZWOzBibl2= MYS0JIg> NV\GU3BITE2VTx?= M3\nVWlv\HWlZYOgZZV1d3CqYXf5 NHjQ[FIzODB{OEGzOC=>
U87MG MlrKT4lv[XOnIFHzd4F6 NWrjUY53OSEQvF2= NV\sT4VHPiCq NUiybGlHTE2VTx?= NUnqT3pPWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36= MVuxPVg1QDRyNB?=
U87MG NW\XV3ZiU2mwYYPlJGF{e2G7 NVHY[3hwOSEQvF2= MXu2JIg> NHHUe4dFVVOR M1XvPXBwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;u MnvYNVk5PDh2MES=
U87MG MYPLbY5ie2ViQYPzZZk> NHjG[WcyKM7:TR?= NUTSeI1WPiCq MVrEUXNQ Mk\RSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? MkHiNVk5PDh2MES=
U87MG NI[4bXZMcW6jc3WgRZN{[Xl? MoDsNUDPxE1? M4KxRVYhcA>? M{TMcGROW09? MXzEc4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44> MVOxPVg1QDRyNB?=
COS7 cells expressing EGFP-HDQ74/rheb M{ntcGF2fG:yaHHnfUBCe3OjeR?= MYCwMlIh|ryP M4HTflI1KGh? NUXhPZhnTE2VTx?= Mm\RTY5lfWOnczDheZRweGijZ4m= NX74e|ZEOTh|OUG5OFk>
COS7 cells expressing EGFP-LC3 Mnu0RZV1d3CqYXf5JGF{e2G7 NVu5TWdLOC5{IN88US=> NWGyV5c2OjRiaB?= NWTrbZZ[TE2VTx?= MnjBTY5lfWOnczDheZRweGijZ4m= MWGxPFM6OTl2OR?=
H4 NW[2Z3lmTnWwY4Tpc44hSXO|YYm= NGDtPZQxNjJizszN NIX3cWYzPCCq MXfEUXNQ MnHSTY5kemWjc3XzJJRp\SC{YYTpc{Bw\iCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNkB1dyCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNUBqdiCqdX3hckBJPCClZXzsdy=> MmL4NVgxOjR3OES=
HeLa M4j3cGZ2dmO2aX;uJGF{e2G7 NE[5b2YyODBibl2= NHXKVJQ{PiCq MmC3SG1UVw>? NEHEfFhKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v MnLlNVc2PjN|OEW=
HeLa M2[5dWZ2dmO2aX;uJGF{e2G7 M4[0VlExOCCwTR?= M4\DR|M3KGh? MVTEUXNQ NIjCPVJKdmS3Y3XzJGZTSiCZMkGwNWYhdXW2YX70MZVjcXG3aYTpcmMhcW62ZYLhZ5Rqd25? NH\tZW4yPzV4M{O4OS=>
HeLa NFfRNotHfW6ldHnvckBCe3OjeR?= M3\6c|ExOCCwTR?= NFH1PWg{PiCq MljYSG1UVw>? NYC1Z4JbUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v NI\SN4syPzV4M{O4OS=>
SYF MXfGeY5kfGmxbjDBd5NigQ>? MlPJNVAxKG6P M1;DdFI1KGh? MUnEUXNQ MX7JcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= NIrlUIUyPzV4M{O4OS=>
SYF M4PDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX1N29xOTByIH7N Mlf3NlQhcA>? NV3LUHNRTE2VTx?= NFnzV5BKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz MV:xO|U3OzN6NR?=
HEK293T MV7BcpRqfmm{YXygRZN{[Xl? Mn\GNUBvVQ>? MUW0JIQ> M1TtSmROW09? MnXnTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFJ3IIfpeIghTUN3MDDv[kAxNjFibl2= M3m5VFE4PDh3NUCx
HEK293T Mn7aRY51cX[rcnHsJGF{e2G7 NF[0enAyKG6P NHnoPGQ1KGR? MYHEUXNQ NIP1fZpKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=> M4[0V|E4PDh3NUCx
PBMC MVnGeY5kfGmxbjDBd5NigQ>? NFnSfokyKG6P M4fOcVE1KGR? MUnEUXNQ MoP4VoVlfWOnczDDR3I2KGSnboPpeJk> NEnhboQyPzR6NUWwNS=>
PBMC NXLpb25pTnWwY4Tpc44hSXO|YYm= MXqxJI5O M3L2[lE1KGR? NHTubWVFVVOR MWnEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=> MXWxO|Q5PTVyMR?=
HEK293 cells NWH2R3pwU2mwYYPlJGF{e2G7 NF\ONlM2OCCwTR?= M{S4[VQ2KG2rbh?= MlToSG1UVw>? NXuyUnYxUW6qaXLpeJMhdVSRUjDrbY5ie2ViYXP0bZZqfHlid3n0bEBKSzVyIH;mJFAvOSCwTR?= M2LiRlE4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc M2DwZmZ2dmO2aX;uJGF{e2G7 MoTwNVAxKG6P MoWzOEBp M3zHdWROW09? NHvHfIlKdmS3Y3XzJIx2[2moZYLhd4UheHKxdHXpckB1emGwcz3zdIxq[2mwZzDpckBFem:|b4DobYxiKG2nbHHuc4die3SncjDTNkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIF6tcJVkKGGwZDDDMYx2[w>? NXX2[GtoOTdzMkiyOlI>
Human mixed lymphocyte NYjjTFJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\KVGFEPSCwTR?= M{DobGROW09? NGTSN3VKSzVyPUGuOkBvVS5? MnPDNVYyQDV6NkW=
Lewis rat lymph node cells M3HUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTMNnpVPSEQvF2= M4XtcWROW09? NU\rUYN[UUN3ME2yMlYh|ryP NH;L[o8yPjF6NUi2OS=>
cells from the thymus of normal BALB/c mice M4\BRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmxNEBvVQ>? M{K1OFczKGh? NY\TUY93TE2VTx?= Mn;5TY5pcWKrdIOgcJlueGixcILvcIln\XKjdHnvckApVEGIKTD3bZRpKEmFNUCgc4YhOyCwTR?= NIjzZ5IyODB{MUm0PC=>
MRK-nu-1 NEfSOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwOES1JJBO NInEXVZUSU6JRWK=
OCUB-M NYXpbGxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUSwTlNQUUN3ME21MlI1KHCP NY\yOoxPW0GQR1XS
SF539 MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXITWM2OD1zMT62JJBO MVXTRW5ITVJ?
ES4 NWjwbWhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDiTWM2OD1{MT61JJBO MUHTRW5ITVJ?
RL95-2 M2Xs[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFyNzDwUS=> NVTlR4FmW0GQR1XS
LC-2-ad MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDqTWM2OD12MkOgdG0> MnG3V2FPT0WU
Daudi MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTxcHRKSzVyPUSzOEBxVQ>? NUnOV5lxW0GQR1XS
NTERA-S-cl-D1 NEH6PHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorJTWM2OD12NEOgdG0> NI\0WGNUSU6JRWK=
OS-RC-2 NHG1UndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXuXIpKSzVyPU[1NkBxVQ>? MomzV2FPT0WU
VA-ES-BJ MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTd{MzDwUS=> M3P3W3NCVkeHUh?=
GR-ST M1r5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTh2NjDwUS=> M3TBdHNCVkeHUh?=
SW872 NVjrS2tMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPSTWM2OD16NE[gdG0> MYjTRW5ITVJ?
NOS-1 NGP6bmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrjTWM2OD16N{GgdG0> NYPEeHVNW0GQR1XS
MC116 NXGwRldOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;Xbo1sUUN3ME25PFUheE1? M3XmS3NCVkeHUh?=
NCI-H1355 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7lPIlKSzVyPUGuNFEhdk1? NGrP[o5USU6JRWK=
RPMI-8226 Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHYNIhyUUN3ME2xMlE6KG6P NWHZRY9nW0GQR1XS
TE-15 NGj4[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLGXYJDUUN3ME2xMlM3KG6P NVKwfJRuW0GQR1XS
Ramos-2G6-4C10 Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfT[XV5UUN3ME2xMlQ3KG6P NYnEUXVDW0GQR1XS
KU812 Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwMEGgcm0> NVPkfJZIW0GQR1XS
EW-1 MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe3XmdKSzVyPUKuNVchdk1? MUjTRW5ITVJ?
KS-1 NEfWSlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vC[WlEPTB;Mj60OUBvVQ>? NEOwcGJUSU6JRWK=
SK-LMS-1 M2PIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrzTWM2OD1{LkS5JI5O MWjTRW5ITVJ?
TGBC1TKB NV;6dnlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TqZWlEPTB;Mj62PUBvVQ>? NFLySI9USU6JRWK=
TE-6 M4HvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTGZ4NIUUN3ME2yMlc4KG6P M4nuUXNCVkeHUh?=
ETK-1 NIDGZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH33RmpKSzVyPUKuPFIhdk1? M2PPWnNCVkeHUh?=
BE-13 NUPRcWxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTaeZFKSzVyPUKuPVkhdk1? M4HM[nNCVkeHUh?=
A3-KAW Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jIPWlEPTB;Mj65PUBvVQ>? NHfkfGtUSU6JRWK=
TE-10 M2DLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTNwMzDuUS=> NEDRXldUSU6JRWK=
DOHH-2 M3;EWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnwcJRzUUN3ME2zMlM2KG6P NIrnOWlUSU6JRWK=
ES6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrlfI1KSzVyPUOuOFMhdk1? M4HNZXNCVkeHUh?=
OPM-2 NELMb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr3UI1KSzVyPUSuNVUhdk1? MoDtV2FPT0WU
SH-4 Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTRwM{Sgcm0> MYrTRW5ITVJ?
NB13 M3rvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTRwM{[gcm0> MWLTRW5ITVJ?
HUTU-80 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYflPZpVUUN3ME20MlQzKG6P MWfTRW5ITVJ?
CCRF-CEM MkjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTRwOUSgcm0> NEPNS2tUSU6JRWK=
TGBC24TKB M33GR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\ONWlEPTB;NT61NUBvVQ>? Mnz5V2FPT0WU
697 NXj3cFc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3OfmozUUN3ME22MlI5KG6P NXXF[ZhPW0GQR1XS
J-RT3-T3-5 M2HhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7UO2xKSzVyPU[uOFYhdk1? M3mzXXNCVkeHUh?=
KALS-1 MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i5RWlEPTB;Nj61OkBvVQ>? Mo[xV2FPT0WU
no-10 M3rDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTXTWM2OD15LkK5JI5O MVnTRW5ITVJ?
SK-NEP-1 M4jhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjlTYxlUUN3ME24Mlc6KG6P NX3ucHNEW0GQR1XS
L-540 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17l[WlEPTB;MUCuOFIhdk1? NWnDdHROW0GQR1XS
JiyoyeP-2003 NUHmOYROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\sW2lEPTB;MUCuPVQhdk1? MlzwV2FPT0WU
HH MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDaTWZVUUN3ME2xNU4{QSCwTR?= MnHPV2FPT0WU
SR M2XBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PRNGlEPTB;MUGuOFUhdk1? NFrZVZJUSU6JRWK=
QIMR-WIL NEL6UFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGm0eppKSzVyPUGxMlg2KG6P NU\rfmozW0GQR1XS
A4-Fuk NH7oeXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPBWnlKSzVyPUGzMlEzKG6P NV23cYRFW0GQR1XS
CESS M33PS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITN[FNKSzVyPUGzMlE{KG6P M{jqUHNCVkeHUh?=
KE-37 NE[zU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DNVGlEPTB;MU[uNFchdk1? MlK1V2FPT0WU
SK-UT-1 NWrjcIZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7BTWM2OD1zNj64NUBvVQ>? M4r1cXNCVkeHUh?=
SIG-M5 NIfVPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXIcXI2UUN3ME2xO{4zPSCwTR?= NITndGtUSU6JRWK=
HT NVPpVlAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTF5Lk[gcm0> Mn;5V2FPT0WU
DEL M2\XfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33vW2lEPTB;MUeuPVkhdk1? MUDTRW5ITVJ?
SK-PN-DW M2PiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXZXIhKSzVyPUKwMlI{KG6P NHr0eGxUSU6JRWK=
RPMI-8402 NIrncFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT6V|hKSzVyPUKxMlc4KG6P NH\ZNHdUSU6JRWK=
RPMI-6666 M2LoV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TLfWlEPTB;MkSuOFIhdk1? M4G3U3NCVkeHUh?=
NCI-H720 NEPkXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJ3LkSxJI5O NEXRRWJUSU6JRWK=
EW-16 NH6xT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzVTWM2OD1{Nj64O{BvVQ>? MWfTRW5ITVJ?
BL-70 MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTkV3JzUUN3ME2yPE4{QCCwTR?= NI\BOFlUSU6JRWK=
SF126 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHKw[YJKSzVyPUOwMlM5KG6P NH3JcoJUSU6JRWK=
BC-1 M2XD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HQO2lEPTB;M{GuNlYhdk1? M2LZT3NCVkeHUh?=
MHH-PREB-1 NF\5R5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof1TWM2OD1|Mj60OEBvVQ>? MYTTRW5ITVJ?
A101D NEnKbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XE[WlEPTB;M{KuOlIhdk1? Mli1V2FPT0WU
NMC-G1 MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\L[mlEPTB;M{OuOlchdk1? NGHNZ2tUSU6JRWK=
LB1047-RCC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTN2Lk[5JI5O MlvFV2FPT0WU
EM-2 M4nwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVi5e5hOUUN3ME2zPE42OyCwTR?= NGWyeplUSU6JRWK=
COLO-684 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTN7Lkigcm0> NWLiVZZoW0GQR1XS
Becker M4LzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTRzLkC1JI5O MorEV2FPT0WU
BL-41 M1j3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S0UWlEPTB;NEOuOlYhdk1? NXzjOIN1W0GQR1XS
MDA-MB-134-VI MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH0UFJLUUN3ME20OE4xOiCwTR?= NHfNWWJUSU6JRWK=
L-363 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTR2LkezJI5O MX;TRW5ITVJ?
ECC4 NUiyRotvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTR2Lke4JI5O Mo\EV2FPT0WU
A388 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTR2LkiyJI5O MmjjV2FPT0WU
HEL M1\mdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvpTWM2OD12OT63PUBvVQ>? MkfIV2FPT0WU
RKO M2fhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTVyLkK5JI5O MnviV2FPT0WU
KINGS-1 MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFSxVIRKSzVyPUWxMlU2KG6P MmfFV2FPT0WU
EB-3 NXXKZmhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO0TWM2OD13Mj62O{BvVQ>? MUnTRW5ITVJ?
ARH-77 NUT1[3R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrUe3VKSzVyPUWyMlghdk1? M3nscHNCVkeHUh?=
GCIY M2fWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTV|LkS2JI5O NXfTeZhvW0GQR1XS
NCI-H1304 NEL4b5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTV5LkKyJI5O NV\uVGR[W0GQR1XS
KARPAS-299 M4jERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTzR3lKSzVyPU[xMlgzKG6P NULOT4huW0GQR1XS
IA-LM NUDYcnBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnITWM2OD14OD6xN{BvVQ>? M120NHNCVkeHUh?=
GI-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn2W5lOUUN3ME23NE4{QSCwTR?= M1HNd3NCVkeHUh?=
TE-11 M3nZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXrZY5EUUN3ME23O{4yPyCwTR?= Mnv5V2FPT0WU
LS-411N NUPuWWdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rZS2lEPTB;N{euOVchdk1? M1PXVnNCVkeHUh?=
no-11 NWfJSWw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTh|LkK0JI5O MlzkV2FPT0WU
MV-4-11 M3:0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke1TWM2OD16Mz63N{BvVQ>? MWfTRW5ITVJ?
BV-173 NF3qXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3WTWM2OD16Mz65O{BvVQ>? M1vKW3NCVkeHUh?=
CMK NXG3Nm85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fpW2lEPTB;OESuNVYhdk1? M1nhdXNCVkeHUh?=
LC4-1 MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjLTWM2OD16Nj63NkBvVQ>? M1izdnNCVkeHUh?=
COR-L279 NULKcoZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHzTWM2OD16Nz6yOUBvVQ>? NXPBO2xIW0GQR1XS
NCI-H209 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;ITodKSzVyPUi3MlQyKG6P M2nxWnNCVkeHUh?=
Raji M2DLNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHMTWM2OD16OT63NkBvVQ>? MWnTRW5ITVJ?
LB996-RCC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPUTWM2OD17Mz60N{BvVQ>? MojrV2FPT0WU
NCI-H526 NV\WZXhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD2PHlKSzVyPUmzMlU6KG6P NVWyU2FyW0GQR1XS
KGN NWeybYRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTl4LkK5JI5O MkLMV2FPT0WU
MOLT-4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoX6TWM2OD17Nj63PUBvVQ>? M3rEdXNCVkeHUh?=
PF-382 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnJTWM2OD17Nj63PUBvVQ>? MoXLV2FPT0WU
BC-3 Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTl7LkG4JI5O NIi4TXZUSU6JRWK=
KARPAS-422 NF;mdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF35cGtKSzVyPUGwNk4xQSCwTR?= M4n4fnNCVkeHUh?=
SBC-1 NXnZVFh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFyNz63OUBvVQ>? NY\lWnA1W0GQR1XS
LC-1F NFOwOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS3TWM2OD1zMEiuNFUhdk1? NFf4NVBUSU6JRWK=
GB-1 MnvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFyOT6wNkBvVQ>? MnzzV2FPT0WU
SNB75 MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFzOT62PUBvVQ>? MnfqV2FPT0WU
BB65-RCC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrH[I9KSzVyPUGxPU46OyCwTR?= MnG5V2FPT0WU
NCI-N87 MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfXdYFJUUN3ME2xNlEvQThibl2= M3rsfXNCVkeHUh?=
IST-MEL1 M1[2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF{Mj6zPEBvVQ>? M4Dhe3NCVkeHUh?=
HOP-62 M1;NeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jmVWlEPTB;MUK2Mlg6KG6P M2LpSHNCVkeHUh?=
ACN MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[wdmlEPTB;MUS2Mlc2KG6P MYPTRW5ITVJ?
DMS-114 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXUTWM2OD1zNUCuOlchdk1? NHfDNpJUSU6JRWK=
MLMA M4j3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jsNWlEPTB;MUW5Mlg5KG6P NGrIcGFUSU6JRWK=
HT-144 NXXrd3NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrLV3hLUUN3ME2xOlUvPDNibl2= MnizV2FPT0WU
C2BBe1 NGjEemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF4Nz63OkBvVQ>? MYLTRW5ITVJ?
L-428 NWfu[FM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTF5Nz63JI5O M3:yd3NCVkeHUh?=
DU-4475 NUDHUo5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrrOHRnUUN3ME2xPFcvPjhibl2= NEDQVG1USU6JRWK=
CP67-MEL M33nSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17rR2lEPTB;MUm5MlM5KG6P NGrZXWRUSU6JRWK=
MEG-01 NI\YNnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJyMT65OkBvVQ>? MYrTRW5ITVJ?
IST-SL2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP4XFVKSzVyPUKwPE43OyCwTR?= NInSXG5USU6JRWK=
ES8 M{TMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzZfIZKSzVyPUKyOU46PCCwTR?= NHPBc4lUSU6JRWK=
COLO-800 M{fjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzEc3l3UUN3ME2yN|UvOjhibl2= NVrEV|ZTW0GQR1XS
MFH-ino M3\U[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXZTZdtUUN3ME2yN|UvQDRibl2= NVKydmxbW0GQR1XS
OVCAR-4 M1vMeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnwSmtEUUN3ME2yN|cvOjRibl2= MUTTRW5ITVJ?
PSN1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;hb2hKSzVyPUK0Nk44OSCwTR?= NFjmUoZUSU6JRWK=
EW-12 MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fM[GlEPTB;MkSzMlEhdk1? M{LJSXNCVkeHUh?=
HCC1599 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ4MT60O{BvVQ>? MX\TRW5ITVJ?
SJSA-1 MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES2NZFKSzVyPUK3NU41PiCwTR?= NXXxemdbW0GQR1XS
ST486 MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUKwXYV6UUN3ME2yPVYvOTRibl2= M1njdnNCVkeHUh?=
NOMO-1 NVvKOmFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;MXoVWUUN3ME2zNFAvOjFibl2= MkTwV2FPT0WU
MN-60 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPuTWM2OD1|MEWuN|Ihdk1? M2jOWXNCVkeHUh?=
HCC1187 MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[4TWM2OD1|MEeuNlUhdk1? NYLCc3JpW0GQR1XS
SW982 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXkWJdKSzVyPUOxOE44PSCwTR?= NEnQW3VUSU6JRWK=
LB647-SCLC Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrzUWxxUUN3ME2zNlgvPzFibl2= MUXTRW5ITVJ?
HC-1 MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLyTWM2OD1|M{WuOUBvVQ>? NIfrZVJUSU6JRWK=
EHEB MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfrOGtKSzVyPUOzO{42OiCwTR?= M1vYd3NCVkeHUh?=
TUR NVqxUZdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPyZoxDUUN3ME2zOlMvQTVibl2= NG\TSXdUSU6JRWK=
LU-139 M3fKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{iwTGlEPTB;M{e4MlAzKG6P NHLTWHVUSU6JRWK=
NB1 NXPYdlJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfIT3RKSzVyPUO4OE41PSCwTR?= NHLrWI9USU6JRWK=
BB30-HNC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTN6OD6zNkBvVQ>? M1LHOHNCVkeHUh?=
HAL-01 M33KZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTN6OT6yOkBvVQ>? M33zZ3NCVkeHUh?=
K5 NIr4SllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7wXGVDUUN3ME20NVEvOzdibl2= MYPTRW5ITVJ?
MZ2-MEL Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;IV4xKSzVyPUSxN{43PCCwTR?= MVXTRW5ITVJ?
RXF393 NFfuZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37LSGlEPTB;NEG2MlQ2KG6P MnTUV2FPT0WU
NCI-H1648 NIDofXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fJVWlEPTB;NEG3MlU{KG6P NYXPXGF3W0GQR1XS
TE-12 MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF70XYJKSzVyPUSzOE4zPiCwTR?= NYD1[FNwW0GQR1XS
EoL-1- M4HncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPYUXZKSzVyPUSzO{46QCCwTR?= MlThV2FPT0WU
JAR MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TKbWlEPTB;NEO4MlYzKG6P MXfTRW5ITVJ?
DSH1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DhVmlEPTB;NEW4MlkyKG6P MmL4V2FPT0WU
NCI-H187 MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrZOZZKSzVyPUS2Nk45OSCwTR?= NEPsRpFUSU6JRWK=
HCE-4 NWX2NWZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnLfIw4UUN3ME20O|cvPjZibl2= MYjTRW5ITVJ?
8-MG-BA NH:zUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LJfGlEPTB;NUixMlUzKG6P M3u2VXNCVkeHUh?=
KLE NFvoUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTV6NT6yJI5O NUnNU3J3W0GQR1XS
KNS-42 Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTV6Nj64NUBvVQ>? MnL1V2FPT0WU
MSTO-211H MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTEXHF4UUN3ME22NFkvPzRibl2= NFTVfpBUSU6JRWK=
GDM-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTZzND6wPUBvVQ>? NXHyNG1qW0GQR1XS
TE-1 M2nPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYexN5lGUUN3ME22OFYvOTJibl2= NGe1SYFUSU6JRWK=
BT-474 M1zITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\SOHdKSzVyPU[0O{4xPiCwTR?= NEO4RllUSU6JRWK=
KARPAS-45 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTZ2Nz62JI5O M3\nW3NCVkeHUh?=
MOLT-16 NUmxXnFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H6WGlEPTB;NkS3Mlk{KG6P NGfBfJVUSU6JRWK=
KURAMOCHI M1z6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrpco0{UUN3ME22OVcvPTFibl2= MmntV2FPT0WU
K-562 MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7DO5dlUUN3ME22OlkvPTFibl2= MkHtV2FPT0WU
EKVX NYLmXlh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPLTWM2OD14N{KuO|Ehdk1? NHK4WWdUSU6JRWK=
GAK NYHyZYdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTZ5NT6zJI5O NVTIfFF{W0GQR1XS
NCI-SNU-5 MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HmOmlEPTB;NkmwMlAyKG6P MWXTRW5ITVJ?
NCI-H2126 NHPSNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrOboNnUUN3ME23NlYvQDdibl2= MmjSV2FPT0WU
CTV-1 MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzoT3E5UUN3ME23OFQvQSCwTR?= M4XoeXNCVkeHUh?=
SW962 NF7D[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDSTWM2OD15NEiuOFQhdk1? MUnTRW5ITVJ?
MONO-MAC-6 NW\JVFdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHCUmNKSzVyPUe1Ok46OyCwTR?= NEPwRXZUSU6JRWK=
NCI-H748 NIfYdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTd3OD65PUBvVQ>? MnvnV2FPT0WU
NCI-H524 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f4T2lEPTB;N{iwMlc{KG6P NWXQRYt[W0GQR1XS
LS-123 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4THWGlEPTB;N{m1MlY6KG6P MVfTRW5ITVJ?
NB7 M4H6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRThzND6xOEBvVQ>? MWXTRW5ITVJ?
LS-1034 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;rUWlEPTB;OEK4Mlk5KG6P M4LZR3NCVkeHUh?=
TE-5 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHiyOXRKSzVyPUi4N{42PiCwTR?= NUTrTpluW0GQR1XS
A704 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\k[WlEPTB;OEm5MlE2KG6P MX3TRW5ITVJ?
TK10 NHGxepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;hc2RKSzVyPUmxOk4xOyCwTR?= MVvTRW5ITVJ?
NCI-H345 M1zLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DKfWlEPTB;OUSzMlIzKG6P NITkbW5USU6JRWK=
CGTH-W-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTl2OD6xN{BvVQ>? MlXwV2FPT0WU
NCI-H510A M3XvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLPcYRQUUN3ME25PFUvOTJibl2= MYDTRW5ITVJ?
NCI-H1963 NEe4U5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETiNXJKSzVyPUGuNFMzQTJizszN NXj3[JJFW0GQR1XS
SCC-3 NXnHN3lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGG5V5dKSzVyPUGuNFM1OTRizszN M1LPWnNCVkeHUh?=
EW-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofETWM2OD1zLkC4O|Q{KM7:TR?= NGT5cW9USU6JRWK=
CPC-N MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXWT4k2UUN3ME2xMlA5QCEQvF2= MUnTRW5ITVJ?
NCI-H1417 Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTFwMUKyOkDPxE1? M1;jT3NCVkeHUh?=
DG-75 NY\MUmd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;DTWM2OD1zLkG2Nlg2KM7:TR?= NHe3SXVUSU6JRWK=
HD-MY-Z MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\2PGU2UUN3ME2xMlE3PDF4IN88US=> NUXGT|lYW0GQR1XS
ATN-1 M1POe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzEOmoxUUN3ME2xMlI3OjB7IN88US=> MUfTRW5ITVJ?
KM-H2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfDR5FiUUN3ME2xMlI3PDB6IN88US=> Mn;2V2FPT0WU
NCI-H2081 M4jVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDPTXBQUUN3ME2xMlI3PjN5IN88US=> NX\xTVBPW0GQR1XS
HL-60 M13SSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXRTVJKSzVyPUGuNlY6PTlizszN NUjwUXlSW0GQR1XS
DB MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PxS2lEPTB;MT6yO|I1OiEQvF2= M1yyUHNCVkeHUh?=
NCI-H1522 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TlOmlEPTB;MT6yPFg5PyEQvF2= M2nWfHNCVkeHUh?=
AM-38 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzFd5BWUUN3ME2xMlMxPzJizszN M2nZ[HNCVkeHUh?=
NCI-H446 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFwM{KxNlEh|ryP M1qycXNCVkeHUh?=
SU-DHL-1 NHzWWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGi2W4xKSzVyPUGuN|I5ODFizszN MVzTRW5ITVJ?
NH-12 M4K2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrXRoZuUUN3ME2xMlM3Ozd2IN88US=> NGD1T4lUSU6JRWK=
DMS-79 NHizc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37wOmlEPTB;MT6zOlg3PiEQvF2= M376eXNCVkeHUh?=
NCI-H716 M3K4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTFwM{i5PFYh|ryP NF3lPJBUSU6JRWK=
ML-2 NHnOdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1npRWlEPTB;MT60NVUzQSEQvF2= Ml3kV2FPT0WU
NB10 M1nSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPWTWM2OD1zLkS2OlMzKM7:TR?= MVLTRW5ITVJ?
ONS-76 NWLNcHNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NISwUWdKSzVyPUGuOVM2PjlizszN MXjTRW5ITVJ?
LOUCY NHnmSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH70XW5KSzVyPUGuOVQ3PTdizszN MnToV2FPT0WU
SCLC-21H MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rzZmlEPTB;MT61PFU5OiEQvF2= MX;TRW5ITVJ?
TGW MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\oWWlEPTB;MT62N|k4PSEQvF2= MVrTRW5ITVJ?
LXF-289 NXnWNZBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXNNW9KSzVyPUGuO|MzPjhizszN NILqNVBUSU6JRWK=
BB49-HNC M3XOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnWyTWM2OD1zLkezOVg3KM7:TR?= MmTNV2FPT0WU
NCI-H747 NInm[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fjeWlEPTB;MT63OVM1PiEQvF2= MULTRW5ITVJ?
LU-165 NIfvZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojjTWM2OD1zLki0PVg3KM7:TR?= NVTQdWExW0GQR1XS
OMC-1 NYruTJk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3WwfGlEPTB;MT65OVA3PiEQvF2= NILYRVdUSU6JRWK=
RCC10RGB NX6wV4V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\pTWM2OD1zLkm1PFE4KM7:TR?= M1PyVXNCVkeHUh?=
SW684 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFwOU[wPVkh|ryP NHHhXY5USU6JRWK=
TE-8 MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LpVWlEPTB;Mj6wOVU2QSEQvF2= NVTWWmtqW0GQR1XS
SK-N-DZ NXn6[YVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJwMUOyO|Qh|ryP M2POc3NCVkeHUh?=
EVSA-T MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJwMUezNVUh|ryP NF\sepFUSU6JRWK=
KASUMI-1 MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnLNXF7UUN3ME2yMlE5QDF3IN88US=> M1\GeXNCVkeHUh?=
NKM-1 NWHFRZlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17MNGlEPTB;Mj6yOVQ4OiEQvF2= NY\tW4RwW0GQR1XS
CAL-148 M3fscmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzETWM2OD1{LkOzOlE1KM7:TR?= MWnTRW5ITVJ?
NCI-H64 NGCxWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF22NVhKSzVyPUKuN|QzOzJizszN NH7wOYpUSU6JRWK=
KNS-81-FD M{f1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJwM{[2NkDPxE1? NYjVfVlqW0GQR1XS
KM12 M1Hzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnSbXJOUUN3ME2yMlQxQDN7IN88US=> MmriV2FPT0WU
SW954 NVHjd2szT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrPdY1KSzVyPUKuOFc4PzlizszN NFy1RXVUSU6JRWK=
NCI-H1395 NXXiZlZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPJ[2pKSzVyPUKuOVI3PDVizszN NITIU2pUSU6JRWK=
DJM-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGzTWM2OD1{Lk[wOlMh|ryP M4Hhd3NCVkeHUh?=
COLO-668 MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\3VIZKSzVyPUKuPFI3QTVizszN NHTZWWdUSU6JRWK=
NCI-H1436 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWntRoN1UUN3ME2yMlg2PjF3IN88US=> Mn;CV2FPT0WU
LB2241-RCC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVu2eFZwUUN3ME2yMlg3QDN7IN88US=> M32zVXNCVkeHUh?=
GT3TKB NEXJfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV6zbpdUUUN3ME2yMlg6ODV3IN88US=> NH3jPVRUSU6JRWK=
COLO-824 NYPYd20zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJwOEm3Olgh|ryP NGiyUW9USU6JRWK=
ES1 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJwOEm4O|kh|ryP NGLvVlRUSU6JRWK=
LB771-HNC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;Ee3d5UUN3ME2yMlkxQTR4IN88US=> MUDTRW5ITVJ?
GI-ME-N NFvn[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfVTWM2OD1|LkCwPVA1KM7:TR?= NUm3b5RZW0GQR1XS
NALM-6 M{XPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTNwMEC5N|Mh|ryP NV\Sdlh5W0GQR1XS
LU-134-A M{HpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTNwMEW0NlUh|ryP MUTTRW5ITVJ?
DMS-153 M3fBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTNwMEW4NlQh|ryP NXj3SFhyW0GQR1XS
MZ1-PC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTNwMEmwO|gh|ryP Mn\RV2FPT0WU
NCI-H1155 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPJTWM2OD1|LkGxOlEh|ryP NVj4NoNtW0GQR1XS
CAS-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu0d4lbUUN3ME2zMlE{PzB5IN88US=> MVnTRW5ITVJ?
D-502MG M2jOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfxTHhjUUN3ME2zMlE1OzlizszN MV3TRW5ITVJ?
NCI-H2141 NX7tcItPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITydFhKSzVyPUOuNVc1PTJizszN NH[xeGNUSU6JRWK=
NB6 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS2SYlsUUN3ME2zMlE5OjV7IN88US=> MWTTRW5ITVJ?
NCCIT Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnUOWZ[UUN3ME2zMlIyQDB7IN88US=> M1TVSHNCVkeHUh?=
NB69 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPjdmdKSzVyPUOuN|E5QTFizszN MoW1V2FPT0WU
JVM-2 MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\CTWM2OD1|LkO2OFM{KM7:TR?= MUDTRW5ITVJ?
K052 M1XLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\OeFZbUUN3ME2zMlM4QTZ6IN88US=> M4TscXNCVkeHUh?=
HCC2157 MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXwT2FKSzVyPUOuOVMzOjhizszN MWDTRW5ITVJ?
KMOE-2 MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLwTWM2OD1|LkW0NlQzKM7:TR?= NXHr[m06W0GQR1XS
SF268 NHzqdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjBTWM2OD1|LkexOVU1KM7:TR?= NFjTXW5USU6JRWK=
CHP-126 NHH2fGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jpOGlEPTB;Mz63OlQ2QCEQvF2= NFm0Vm5USU6JRWK=
CP66-MEL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4iwNmlEPTB;Mz63PVA6PCEQvF2= MYrTRW5ITVJ?
NCI-H69 Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTRwMEG5N|Yh|ryP NYT6bmpMW0GQR1XS
A253 NILsUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTRwMEKxNFEh|ryP M1PuOnNCVkeHUh?=
NB14 NFjQSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO4TWM2OD12LkGwOFc6KM7:TR?= NH3Yb4FUSU6JRWK=
NCI-H1694 MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjFTWM2OD12LkGzNVEzKM7:TR?= MWPTRW5ITVJ?
NCI-H2196 NXrDZVVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTRwMUexOlkh|ryP NEf2cXdUSU6JRWK=
TE-9 M36xO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX6WZdKSzVyPUSuNVc2QDJizszN M3;uS3NCVkeHUh?=
D-283MED NWD4T4RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTRwMUi4OEDPxE1? MknyV2FPT0WU
OCI-AML2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrhb2pEUUN3ME20MlE6PDh7IN88US=> M2XIfHNCVkeHUh?=
D-263MG NHrGeFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW0ZYluUUN3ME20MlIzQTZzIN88US=> M3TMeXNCVkeHUh?=
MPP-89 NFX3Z2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLTZoxTUUN3ME20MlI4OzB2IN88US=> MWDTRW5ITVJ?
LAMA-84 M4C2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fnWWlEPTB;ND6zNFQzOSEQvF2= NF20VpNUSU6JRWK=
LB373-MEL-D NFPqb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPPV2VKSzVyPUSuN|Y4QDlizszN NVfaXVlYW0GQR1XS
UACC-257 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3qwNWlEPTB;ND6zPVU{PCEQvF2= NXXaO3dbW0GQR1XS
MC-CAR NHXKd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTRwNEO5PUDPxE1? MXjTRW5ITVJ?
COLO-320-HSR MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f2ZmlEPTB;ND60OFQzPyEQvF2= MWHTRW5ITVJ?
P30-OHK M1\UOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPHTWM2OD12Lk[2OVgyKM7:TR?= MknQV2FPT0WU
UACC-812 M4P0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe2UZgzUUN3ME20MlY6OTZzIN88US=> MlfaV2FPT0WU
CTB-1 MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLLTWM2OD12LkexOVU2KM7:TR?= NITUcJJUSU6JRWK=
ALL-PO MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D1RmlEPTB;ND64OFA4PyEQvF2= NVXhSVRoW0GQR1XS
SK-MEL-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe3RVZvUUN3ME20Mlg3QTV3IN88US=> Ml3HV2FPT0WU
TC-YIK M{fG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;kfmlEPTB;ND65O|k1OiEQvF2= MXjTRW5ITVJ?
NCI-H1882 MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLCTWM2OD13LkCyNFAyKM7:TR?= M2LHRnNCVkeHUh?=
MHH-CALL-2 Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX3WJVKSzVyPUWuNFUxPDJizszN NHPsNZlUSU6JRWK=
U-87-MG M1LPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTTTWM2OD13LkC5OFY3KM7:TR?= M1LQVXNCVkeHUh?=
NCI-H1092 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fzbmlEPTB;NT6yOlU2PSEQvF2= MnLIV2FPT0WU
TE-441-T NVnpTVhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXtblhKSzVyPUWuNlc5OiEQvF2= NGK5XmtUSU6JRWK=
SK-MEL-1 NXXzNogxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC5TmFwUUN3ME21MlI6ODR2IN88US=> M{\kb3NCVkeHUh?=
EW-22 NX3qWpBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorETWM2OD13LkK5OFY3KM7:TR?= NFm4bGRUSU6JRWK=
MZ7-mel NHjQPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLYTWM2OD13LkSwOlkyKM7:TR?= MnnSV2FPT0WU
LP-1 M3ezTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTzd5JPUUN3ME21MlQyOjlzIN88US=> MVHTRW5ITVJ?
NCI-SNU-16 M2\UfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jBXWlEPTB;NT62OFA4PCEQvF2= M{P3Z3NCVkeHUh?=
LU-65 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTVwN{[zO|Mh|ryP M1nmO3NCVkeHUh?=
CW-2 MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHiwPJlKSzVyPUWuPFU6PTlizszN M2DZOXNCVkeHUh?=
WSU-NHL MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\KTWM2OD13Lkm1NVc1KM7:TR?= NXPNeVU4W0GQR1XS
IST-MES1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLWWFdpUUN3ME21Mlk2PDR|IN88US=> M3rObHNCVkeHUh?=
U-266 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIm1eYxKSzVyPUWuPVgzODJizszN M2jy[3NCVkeHUh?=
TALL-1 NVXuTldYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTZwMUS2PFgh|ryP NHXyUVRUSU6JRWK=
Calu-6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q4dmlEPTB;Nj6xOVMyPiEQvF2= NYnEPW9pW0GQR1XS
MMAC-SF NEnCOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHxTWM2OD14LkG4OVU3KM7:TR?= NXz4fFdjW0GQR1XS
NCI-H82 NUPPW3RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFuxSpFKSzVyPU[uNlA1QDlizszN MkHrV2FPT0WU
RS4-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jYXmlEPTB;Nj6yOVg6PyEQvF2= MmPjV2FPT0WU
SNU-C2B MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTZwNEC5Olkh|ryP NF\IcFZUSU6JRWK=
BOKU NFTncIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvHTWM2OD14LkS3OVk4KM7:TR?= M{C5cHNCVkeHUh?=
C8166 NVzRb|hIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHPV|ZKSzVyPU[uOVU6OTJizszN NWHNfZE6W0GQR1XS
D-247MG M1TwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfhdXNQUUN3ME23MlA1OzR5IN88US=> M4e1[3NCVkeHUh?=
EW-18 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTdwMEeyPVIh|ryP M3;lSnNCVkeHUh?=
KG-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DURmlEPTB;Nz62Nlc{QCEQvF2= NYW0SotWW0GQR1XS
REH MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrsc4FKSzVyPUeuOlgyODlizszN M4HTfHNCVkeHUh?=
U-698-M M33ZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z5XWlEPTB;Nz64OFMyPSEQvF2= Ml:xV2FPT0WU
KP-N-RT-BM-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTdwOUOwNlkh|ryP MnLEV2FPT0WU
MS-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTdwOU[wOFEh|ryP M2L3SHNCVkeHUh?=
SNU-C1 Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTdwOUixPVIh|ryP NH\m[pNUSU6JRWK=
SK-MM-2 M1HWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2j2R2lEPTB;OD6yOlA3PSEQvF2= NF7XWVZUSU6JRWK=
LAN-6 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDD[YJKSzVyPUiuN|AxODFizszN MULTRW5ITVJ?
NEC8 NHvze|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jBSmlEPTB;OD6zNFY6OSEQvF2= M33OdHNCVkeHUh?=
NCI-H1770 NWfJN4pOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Pzc2lEPTB;OD6zPFAxOiEQvF2= NFnzfG5USU6JRWK=
D-336MG M33jSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRThwNECxNVYh|ryP NYLhPXhqW0GQR1XS
COLO-829 NIHHfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[0TWM2OD16LkS4PFc6KM7:TR?= NXvqVWNrW0GQR1XS
LS-513 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTQNGNiUUN3ME24MlU6PTl7IN88US=> M1rO[nNCVkeHUh?=
YT Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\VOIlmUUN3ME24MlYzPDJ5IN88US=> M1\aVXNCVkeHUh?=
EW-24 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfYSFg4UUN3ME24Mlc3PTRizszN NUHGfJV7W0GQR1XS
IST-SL1 NH3lZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnrWlFKSzVyPUiuPFY2PDNizszN M3jXTXNCVkeHUh?=
CA46 NV;BfllJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRThwOUWwPVgh|ryP MX\TRW5ITVJ?
NCI-H1838 MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP1TWM2OD16Lkm4OlAzKM7:TR?= M{Xld3NCVkeHUh?=
NCI-H719 NI\oXHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr4TWM2OD17LkK1Nlc6KM7:TR?= NE[5OXpUSU6JRWK=
HCE-T MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fmdGlEPTB;OT6zNFg2OSEQvF2= MlS0V2FPT0WU
A498 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGC3UFlKSzVyPUmuN|YyOjRizszN M{TySnNCVkeHUh?=
LB831-BLC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPlTWM2OD17Lke2OVIyKM7:TR?= MXfTRW5ITVJ?
SKM-1 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vIN2lEPTB;OT64OVk3OyEQvF2= NFfaS5FUSU6JRWK=
THP-1 M2HtfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX5TZVpUUN3ME25Mlk3QTF6IN88US=> M131cnNCVkeHUh?=
SHP-77 NELTSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFyLkSwO{DPxE1? MXjTRW5ITVJ?
EW-3 NX[1W2h3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS1TWM2OD1zMD62Nlg6KM7:TR?= M3L1[nNCVkeHUh?=
KY821 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHhTmFTUUN3ME2xNE44PjNizszN MWDTRW5ITVJ?
NCI-SNU-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPGeZIzUUN3ME2xNU4xOjF5IN88US=> NHXM[2ZUSU6JRWK=
HCC2218 NYPKNY5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:1OGlEPTB;MUGuN|k5PiEQvF2= MXTTRW5ITVJ?
IM-9 M3H5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfMb3kzUUN3ME2xNU42OTB4IN88US=> MWrTRW5ITVJ?
NCI-H889 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzUTWM2OD1zMT61N|E{KM7:TR?= MkS2V2FPT0WU
HDLM-2 M4\kOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW0[WtKSzVyPUGyMlQyPTlizszN MlW2V2FPT0WU
LB2518-MEL M1fYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF{Lk[4NVUh|ryP MXXTRW5ITVJ?
NCI-H23 NITHeYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF|LkK0NlUh|ryP Mn\6V2FPT0WU
NB17 NWfzR2d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny2TWM2OD1zMz60OVc6KM7:TR?= MmLVV2FPT0WU
NCI-H322M MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[0N5llUUN3ME2xOE41ODZ6IN88US=> NEDwemJUSU6JRWK=
SUP-T1 MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm1bnJKSzVyPUG0MlQyOyEQvF2= NUTreZN2W0GQR1XS
ES3 NWe4eVd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjHVmRKSzVyPUG1MlA4ODNizszN NGDKTYhUSU6JRWK=
ES5 Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIniXnBKSzVyPUG1MlA4QDdizszN M4LrXXNCVkeHUh?=
NCI-H1650 M{\mUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF3LkS5O|kh|ryP M3Pn[HNCVkeHUh?=
NCI-H226 NVHPRWk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDWTWM2OD1zNT64O|Y5KM7:TR?= NWjwfJlRW0GQR1XS
COR-L88 MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXwT4ZTUUN3ME2xOk4{OTRizszN NVnSWVZ5W0GQR1XS
SCC-15 NEna[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF4LkO4Olkh|ryP MkjmV2FPT0WU
GOTO NWLjW2s6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnNTHRiUUN3ME2xOk41Pzl|IN88US=> MWrTRW5ITVJ?
SIMA NIP6[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rncmlEPTB;MU[uOFgxOiEQvF2= MYLTRW5ITVJ?
NCI-H1299 M2DRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf4NotKSzVyPUG3MlE2QTFizszN NY\BU2JEW0GQR1XS
NCI-H1581 NXKyUod5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVqxdYU6UUN3ME2xO{41OjF7IN88US=> MlfwV2FPT0WU
MHH-NB-11 NGmwPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF5Lkm2PFMh|ryP MXrTRW5ITVJ?
MFM-223 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInteGZKSzVyPUG4MlA2OzhizszN MWLTRW5ITVJ?
ES7 M4fXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrReZVKSzVyPUG4MlU1OzFizszN Mo\ZV2FPT0WU
JVM-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF6LkexO{DPxE1? Mn3LV2FPT0WU
RL Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\TeGlEPTB;MkCuN|g5KM7:TR?= MkfMV2FPT0WU
EC-GI-10 NYLQb3lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnjTWM2OD1{MT6yNFQyKM7:TR?= M3vJdnNCVkeHUh?=
LNCaP-Clone-FGC NGP5Z3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLmTWM2OD1{MT62O|Y5KM7:TR?= Mkf1V2FPT0WU
IMR-5 NF\ueG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL2fHFtUUN3ME2yNU45PDl2IN88US=> M3frb3NCVkeHUh?=
KP-N-YS MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf5e4pKSzVyPUKxMlg4PSEQvF2= NIPtUIdUSU6JRWK=
Mo-T NXXQS41mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJ{LkKxPFUh|ryP MYPTRW5ITVJ?
NCI-H128 MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLETWM2OD1{Mz61PFU{KM7:TR?= MXPTRW5ITVJ?
RH-1 NFvDe5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL5b45LUUN3ME2yN{44QDZ4IN88US=> NWjzcnI2W0GQR1XS
NCI-H2171 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS0TWM2OD1{ND6yOFg2KM7:TR?= M1n5bXNCVkeHUh?=
RPMI-8866 MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfGTWM2OD1{Nj63OFIh|ryP MY\TRW5ITVJ?
SK-N-FI NGThWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M332W2lEPTB;MkeuN|gyOSEQvF2= MmfHV2FPT0WU
LOXIMVI NVzlOFhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJ5LkiwOVEh|ryP MYfTRW5ITVJ?
P31-FUJ MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfabmdKSzVyPUOxMlU{PzRizszN MlnYV2FPT0WU
KMS-12-PE MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rDOWlEPTB;NEmuOVMxOiEQvF2= NUexUFlvW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-mTOR(S2448)/mTOR; 

PubMed: 23991038     


MCF-7-vector and MCF-7-ZNF703 cells were treated with DMSO, 0.1 µM rapamycin, or 1 µM rapamycin for 24 hours before cell lysis. Western blot analysis of lysates using the indicated antibodies. A GAPDH antibody was used as a loading control.

23991038
Growth inhibition assay
Cell proliferation; 

PubMed: 30393233     


(A) Effect of Rapamycin treatment on SK-N-SH cell proliferation. (B) Effect of Rapamycin treatment on SH-SY5Y cell proliferation. Rapamycin, except treatment of 10 µM for 12 h, can obviously inhibited proliferation of NB cells compared with corresponding control group (P<0.05). (*) indicates statistically significant difference with P<0.05.

30393233
Histomorphology
Haematoxylin & Eosin; 

PubMed: 28418837     


Representative pictures of H&E-stained U87MG cells. The fusiform cell body observed in control cells A. disappears in cells exposed to increasing doses of rapamycin for 24 h B.-E. Rapamycin produces a dose-dependent increase in the diameter of the cell body which develops a pyramidal shape. 1 nM (B); 10 nM (C); 100 nM (D); 1 μM (E) of rapamycin exposure.

28418837
Immunofluorescence
NeuN; 

PubMed: 28418837     


Immune-fluorescence of U87MG cells treated with vehicle A.-D. and rapamycin at the dose of 10 nM E.-H.; 100 nM I.-L.; 1 μM M.-P. In the first line cells were stained for the late post-mitotic neuronal marker NeuN. In the second line cells were stained for the nuclear dye DAPI. In the third line the merging between NeuN (green) and DAPI (blue) fluorescence is shown. In the fourth line a high magnification of the squared insert of line three is shown.

p62/Beclin; 

PubMed: 28819214     


(C,D) Rapamycin treatment reduced the aggregate level of p62 and Beclin 1 in cardiomyocytes. NRVCs were transduced with Ad-Nef or Ad-null for 48 hours and cells were fixed with 4% PFA. Fixed cells were stained with p62 and Beclin 1 antibody. 

28418837 28819214
ELISA
Type III collagen/Fibronectin; 

PubMed: 23364979     


(A) Rapamycin inhibits TGF-β1-induced type III collagen level in the culture medium of human lung fibroblast, evidenced by ELISA. Type III collagen level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. No significant difference was found between different concentration groups of rapamycin. (B) Rapamycin inhibits TGF-β1-induced fibronectin level in the culture medium of human lung fibroblast, shown by ELISA. Fibronectin level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. Values are mean of three independent experiments. No significant difference was found between different concentration groups of rapamycin. *p<0.05 vs. control; †p<0.05 vs. TGF-β1 group. TGF-β1, transforming growth factor β1.

23364979
In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03433183 Recruiting Drug: Selumetinib|Drug: Sirolimus Malignant Peripheral Nerve Sheath Tumors|Neurofibromatosis 1 Sarcoma Alliance for Research through Collaboration|United States Department of Defense|AstraZeneca October 2 2019 Phase 2
NCT03933904 Recruiting Drug: Sirolimus Castleman Disease|Castleman''s Disease Multicentric University of Pennsylvania September 25 2019 Phase 2
NCT03972592 Recruiting Drug: Topical 0.1% Sirolimus|Drug: Topical Vehicle Vascular Malformations|Lymphatic Malformation University Hospital Tours|University Hospital Angers June 5 2019 Phase 2
NCT03811717 Completed Other: FAST+EX|Other: FAST Skeletal Muscle Energetics Queen''s University|University of Waterloo January 14 2019 Not Applicable
NCT03765944 Completed Drug: sirolimus Bioequivalence Study Nobelpharma December 5 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID